PsA still has ^mortality vs general marched pop’n. Can we do better for our pts? Abstr#1476 @RheumNow @CRASCRRheum #ACR20 https://t.co/aDkTF9dFF0

• https://twitter.com/lihi_eder/status/1325574894604660737

When do you tend to change tx strategies in PsA? #ACR20 @RheumNow

Despite 30% decrease in mortality over the past 2 decades, the mortality gap remains in psoriasis and #PsA. #ACR20 Abstract #1476 by @Keith_Colaco. @NPF @WCRInstitute @researchuoft @RheumNow @rheum_cat https://t.co/CXTELMJh8P

#Multimorbidity in #RheumaticDisease: Abs#1466: -Highly prevalent across RA, PsA, gout & OA -Highest burden in #gout Important study highlighting need to recognise burden of MM in #rheumatology patients for holistic optimised management. #ACR20 @RheumNow https://t.co/esinnHoUME https://t.co/bApXfx7hOU

• Multimorbidity in Rheumatoid Arthritis, Psoriatic Arthritis, Gout, and Osteoart…

Dr England presents on multimorbidity in RA, PsA, gout, and OA within RISE registry. Highly prevalent in all 4 but most pronounced in gout and RA. Critical to recognise and manage. @rheumnow #ACR20 Abstr#1466 https://t.co/XtwIfJnVXV

Are there distinct groups of axSpA and PsA patients with peripheral arthritis. This study shows heterogeneous patterns of peripheral involvement and overlap in SpA and PsA groups @RheumNow #ACR20 Abstr#1311 https://t.co/2Q5FH6ZrWm

Wanna learn about T2T PsA abstracts from #ACR20? Here are my highlights! @RheumNow https://t.co/0X7FF3rwTz

• Treat to Target for PsA Patients Abstracts: Dr. Rachel Tate | RheumNow

SELECT-PsA Phase 3, Placebo, Active controlled trial of Upadacitinib in PsA 1⃣UPA 15mg or 30mg - ⬆️PROs vs. Placebo thru 24wks 2⃣Similar improvement in UPA 15mg vs. 30mg 3⃣Both doses similar or > Adalimumab @RheumNow #ACR20 Abs#1341 #ACRbest https://t.co/yu9IEX8tf0

#ACR20👀🔥🔥@AliDuarteMD Population epi revealed: ⭐️Markedly increased SLE incidence ⭐️Drastically increased SLE prevalence Better epi saves 🫀, saves💰, informs better🧪🔬and💉🩺@RheumNow @LupusOrg @LupusResearch https://t.co/CTzJuB9DVk

NT-proBNP and TnI predicted cardiovascular events in patients with PsO or PsA. Abs#1328 Do you measure/monitor for cardiovascular disease in your psoriatic patients? @RheumNow #ACR20

UPA was efficacious in treating axial symptoms in pts with PsA. #ABS1372 #ACR20 @RheumNow https://t.co/ut6L0jM9WJ https://t.co/6H2N3ap6eI

• Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis and Ax…

Shifting Treatment Paradigms in Psoriatic Arthritis: Dr. Eric Ruderman (@JointMD) Chicago-based Dr. Eric Ruderman discussed the shifting treatment paradigms in psoriatic arthritis by reviewing abstracts #0504 and #2026 at #ACR20. https://t.co/jsLkgWG63v https://t.co/h3r2oapOij

• https://bit.ly/3eEfXIj

Two Psoriatic Arthritis Studies: Dr Robert Chao (@doctorRBC) Dr. Robert Chao discusses abstracts #0375 and #0381 as presented Friday at the #ACR20 annual meeting. https://t.co/9VpvS1eE2u https://t.co/z2pshtzDeZ

• https://bit.ly/38hg6jt